Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.3.0.814
Commitments and Contingencies (Details Textual)
 1 Months Ended 9 Months Ended 12 Months Ended
Jul. 09, 2015
USD ($)
Jul. 07, 2014
shares
Jan. 31, 2012
USD ($)
Sep. 30, 2015
USD ($)
ft²
Dec. 31, 2014
USD ($)
Commitments and Contingencies [Line Items]          
Area of Land | ft²       2,390  
License Expiration Period     12 years    
Net Extinguished, Fair Value of Stock Consideration Received         $ 240,000
License Costs       $ 12,500  
Payments for Royalties     $ 100,000    
Operating Leases, Future Minimum Payments Due       $ 12,500  
Description on Civil Penalties for Failure to File an FBAR       greater of $100,000 per year or 50%  
Description of Lessor Leasing Arrangements, Operating Leases       The Company executed a lease agreement in January 2013 which expired in June 2013. The Company exercised its option to continue the lease on a month to month basis. The agreement is cancellable by either party with one month notice. The Company has executed a new 2 year lease agreement commencing in December 2015 and ending in December 2017  
Licensor [Member]          
Commitments and Contingencies [Line Items]          
Area of Land | ft²       4,516  
Stock Issued During Period, Shares, Other | shares   15,036      
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]          
Commitments and Contingencies [Line Items]          
Payments to Acquire Intangible Assets $ 1,000,000        
Proceeds from Sale of Intangible Assets $ 32,500,000